Femara receives FDA nod for new indication

Article

Novartis has been given the OK to market its aromatase inhibitor, Femara (letrozole), as a treatment for use after surgery in postmenopausal women with hormone-sensitive early breast cancer. Approval of the new indication was based on results from the Breast International Group (BIG 1-98) study, which showed an additional 21% reduction in risk for cancer recurrence over tamoxifen therapy and a 27% reduction in the risk of cancer metastases to distant parts of the body. The drug was given a six-month priority review.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.